Details of the Drug

General Information of Drug (ID: DMKBYWI)

Drug Name
Trifluoperazine
Synonyms
Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 407.5
Topological Polar Surface Area (xlogp) 5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 - 20 hours [3]
Metabolism
The drug is metabolized via the hepatic [4]
Water Solubility
The ability of drug to dissolve in water is measured as 50 mg/mL [2]
Chemical Identifiers
Formula
C21H24F3N3S
IUPAC Name
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
Canonical SMILES
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
InChI
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
InChIKey
ZEWQUBUPAILYHI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5566
ChEBI ID
CHEBI:45951
CAS Number
117-89-5
DrugBank ID
DB00831
TTD ID
D0R4OM
VARIDT ID
DR00664
INTEDE ID
DR1641
ACDINA ID
D00703

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calmodulin (CALM) TTV3NH6 CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN Inhibitor [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [7]
Dimethylaniline oxidase 2 (FMO2) DEIASEZ FMO2_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Schizophrenia [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calmodulin (CALM) DTT CALM 6.44E-01 0.09 0.15
Calmodulin (CALM) DTT CALM 5.89E-01 -3.28E-04 -1.09E-03
P-glycoprotein 1 (ABCB1) DTP P-GP 1.19E-01 -1.32E-01 -2.77E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 1.65E-01 -1.47E-01 -4.48E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.73E-02 6.49E-02 3.07E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.45E-01 2.07E-02 1.74E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trifluoperazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Quetiapine. Schizophrenia [6A20] [31]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Mesoridazine. Schizophrenia [6A20] [31]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Aripiprazole. Schizophrenia [6A20] [32]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Iloperidone. Schizophrenia [6A20] [31]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Paliperidone. Schizophrenia [6A20] [31]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Perphenazine. Schizophrenia [6A20] [32]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Molindone. Schizophrenia [6A20] [32]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Thiothixene. Schizophrenia [6A20] [32]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Amisulpride. Schizophrenia [6A20] [33]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Asenapine. Schizophrenia [6A20] [31]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Pimozide. Schizophrenia [6A20] [34]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Trifluoperazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Ivosidenib. Acute myeloid leukaemia [2A60] [35]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Midostaurin. Acute myeloid leukaemia [2A60] [31]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Idarubicin. Acute myeloid leukaemia [2A60] [31]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Arn-509. Acute myeloid leukaemia [2A60] [34]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Gilteritinib. Acute myeloid leukaemia [2A60] [36]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Trifluoperazine and Oliceridine. Acute pain [MG31] [37]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Memantine. Alzheimer disease [8A20] [32]
Rivastigmine DMG629M Moderate Antagonize the effect of Trifluoperazine when combined with Rivastigmine. Alzheimer disease [8A20] [39]
Donepezil DMIYG7Z Moderate Antagonize the effect of Trifluoperazine when combined with Donepezil. Alzheimer disease [8A20] [39]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Trifluoperazine and Metronidazole. Amoebiasis [1A36] [40]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Trifluoperazine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [41]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Trifluoperazine and Trimethaphan. Aneurysm/dissection [BD50] [42]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Ivabradine. Angina pectoris [BA40] [34]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Bepridil. Angina pectoris [BA40] [31]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Dronedarone. Angina pectoris [BA40] [31]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Amyl nitrite. Angina pectoris [BA40] [41]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Trifluoperazine and Nifedipine. Angina pectoris [BA40] [41]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [43]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Cilostazol. Arterial occlusive disease [BD40] [31]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Posaconazole. Aspergillosis [1F20] [31]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Levalbuterol. Asthma [CA23] [44]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Terbutaline. Asthma [CA23] [45]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Pirbuterol. Asthma [CA23] [45]
Ephedrine DMMV0KW Moderate Antagonize the effect of Trifluoperazine when combined with Ephedrine. Asthma [CA23] [46]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Salbutamol. Asthma [CA23] [44]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Formoterol. Asthma [CA23] [45]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Trifluoperazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [46]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Trifluoperazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [47]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [48]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [31]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Trifluoperazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [31]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [48]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [48]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [48]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [48]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [31]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Telithromycin. Bacterial infection [1A00-1C4Z] [31]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Retigabine. Behcet disease [4A62] [31]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Cariprazine. Bipolar disorder [6A60] [32]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Trifluoperazine and Loperamide. Bowel habit change [ME05] [49]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Eribulin. Breast cancer [2C60-2C6Y] [31]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Lapatinib. Breast cancer [2C60-2C6Y] [31]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Trifluoperazine when combined with Acetylcholine. Cataract [9B10] [50]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [51]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [52]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [45]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [44]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [52]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [45]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [52]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [45]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [45]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Trifluoperazine and Dihydrocodeine. Chronic pain [MG30] [53]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Isoproterenol. Conduction disorder [BC63] [44]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Halothane. Corneal disease [9A76-9A78] [31]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Sevoflurane. Corneal disease [9A76-9A78] [31]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Trifluoperazine and Remifentanil. Corneal disease [9A76-9A78] [37]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Probucol. Coronary atherosclerosis [BA80] [31]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Clofazimine. Crohn disease [DD70] [54]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Mifepristone. Cushing syndrome [5A70] [31]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Pasireotide. Cushing syndrome [5A70] [31]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Osilodrostat. Cushing syndrome [5A70] [34]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Cyclandelate. Dementia [6D80-6D8Z] [41]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Sertraline. Depression [6A70-6A7Z] [31]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Cyclobenzaprine. Depression [6A70-6A7Z] [32]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Trifluoperazine and Selegiline. Depression [6A70-6A7Z] [55]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Trifluoperazine and Isocarboxazid. Depression [6A70-6A7Z] [55]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Escitalopram. Depression [6A70-6A7Z] [31]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Trifluoperazine and OPC-34712. Depression [6A70-6A7Z] [32]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Trifluoperazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [47]
Doxepin DMPI98T Moderate Increased plasma concentrations of Trifluoperazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [47]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Maprotiline. Depression [6A70-6A7Z] [32]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Trifluoperazine and Esketamine. Depression [6A70-6A7Z] [40]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Mepenzolate. Digestive system disease [DE2Z] [32]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Oxybutynine. Discovery agent [N.A.] [32]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Trifluoperazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [56]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Trifluoperazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [57]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Trifluoperazine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [58]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Trifluoperazine and Ethacrynic acid. Essential hypertension [BA00] [42]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Trifluoperazine and Nadolol. Essential hypertension [BA00] [41]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Solifenacin. Functional bladder disorder [GC50] [31]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Tolterodine. Functional bladder disorder [GC50] [32]
Terbinafine DMI6HUW Moderate Decreased metabolism of Trifluoperazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [59]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Ketoconazole. Fungal infection [1F29-1F2F] [31]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [31]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Trifluoperazine and Carvedilol. Heart failure [BD10-BD1Z] [41]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Chlorothiazide. Heart failure [BD10-BD1Z] [40]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Bumetanide. Heart failure [BD10-BD1Z] [40]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Trifluoperazine and Procarbazine. Hodgkin lymphoma [2B30] [55]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [60]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [61]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [31]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Isosorbide mononitrate. Hydrocephalus [8D64] [41]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Trifluoperazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [40]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Trifluoperazine and Eprosartan. Hypertension [BA00-BA04] [41]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Trifluoperazine and Acebutolol. Hypertension [BA00-BA04] [41]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Trifluoperazine and Captopril. Hypertension [BA00-BA04] [41]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Trifluoperazine and Penbutolol. Hypertension [BA00-BA04] [41]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Trifluoperazine and Nebivolol. Hypertension [BA00-BA04] [41]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Trifluoperazine and TAK-491. Hypertension [BA00-BA04] [41]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Pindolol. Hypertension [BA00-BA04] [41]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Trifluoperazine and Trichlormethiazide. Hypertension [BA00-BA04] [41]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Diazoxide. Hypertension [BA00-BA04] [41]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Felodipine. Hypertension [BA00-BA04] [41]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Quinapril. Hypertension [BA00-BA04] [41]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Trifluoperazine and Deserpidine. Hypertension [BA00-BA04] [41]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Telmisartan. Hypertension [BA00-BA04] [41]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Trifluoperazine and Irbesartan. Hypertension [BA00-BA04] [41]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Trifluoperazine and Hydralazine. Hypertension [BA00-BA04] [41]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [40]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Clevidipine butyrate. Hypertension [BA00-BA04] [41]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [32]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Amantadine. Influenza [1E30-1E32] [62]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Trifluoperazine and ITI-007. Insomnia [7A00-7A0Z] [32]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Trifluoperazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [31]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Phenolphthalein. Irritable bowel syndrome [DD91] [31]
Physostigmine DM2N0TO Moderate Antagonize the effect of Trifluoperazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [39]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Trifluoperazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [34]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Crizotinib. Lung cancer [2C25] [63]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Ceritinib. Lung cancer [2C25] [31]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Osimertinib. Lung cancer [2C25] [64]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Selpercatinib. Lung cancer [2C25] [34]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Lumefantrine. Malaria [1F40-1F45] [40]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Halofantrine. Malaria [1F40-1F45] [65]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Hydroxychloroquine. Malaria [1F40-1F45] [66]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Primaquine. Malaria [1F40-1F45] [31]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [67]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Vemurafenib. Melanoma [2C30] [31]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and LGX818. Melanoma [2C30] [68]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Trifluoperazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [69]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Trifluoperazine and Lasmiditan. Migraine [8A80] [70]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Trifluoperazine and Flibanserin. Mood disorder [6A60-6E23] [71]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Panobinostat. Multiple myeloma [2A83] [72]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Trifluoperazine and Thalidomide. Multiple myeloma [2A83] [73]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Siponimod. Multiple sclerosis [8A40] [40]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Fingolimod. Multiple sclerosis [8A40] [31]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Ozanimod. Multiple sclerosis [8A40] [74]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Romidepsin. Mycosis fungoides [2B01] [31]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Nilotinib. Myeloproliferative neoplasm [2A20] [31]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Dasatinib. Myeloproliferative neoplasm [2A20] [75]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Phenindamine. Nasopharyngitis [CA00] [32]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Promethazine. Nausea/vomiting [MD90] [32]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Cyclizine. Nausea/vomiting [MD90] [32]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Trifluoperazine and Metoclopramide. Nausea/vomiting [MD90] [76]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Ondansetron. Nausea/vomiting [MD90] [31]
Bupropion DM5PCS7 Major Decreased metabolism of Trifluoperazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [31]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Entrectinib. Non-small cell lung cancer [2C25] [40]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Trifluoperazine when combined with Phendimetrazine. Obesity [5B80-5B81] [46]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Trifluoperazine when combined with Amfepramone. Obesity [5B80-5B81] [46]
Benzphetamine DMIJATC Moderate Antagonize the effect of Trifluoperazine when combined with Benzphetamine. Obesity [5B80-5B81] [46]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Trifluoperazine and Polythiazide. Oedema [MG29] [40]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Levomethadyl Acetate. Opioid use disorder [6C43] [34]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Lofexidine. Opioid use disorder [6C43] [31]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Trifluoperazine and Apraclonidine. Optic nerve disorder [9C40] [77]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Rucaparib. Ovarian cancer [2C73] [31]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Trifluoperazine and Oxymorphone. Pain [MG30-MG3Z] [37]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Trifluoperazine and Dezocine. Pain [MG30-MG3Z] [37]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Trifluoperazine and Nalbuphine. Pain [MG30-MG3Z] [37]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Trifluoperazine when combined with Methamphetamine. Pain [MG30-MG3Z] [78]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Trifluoperazine and Buprenorphine. Pain [MG30-MG3Z] [79]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Trifluoperazine and Hydrocodone. Pain [MG30-MG3Z] [37]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Triclabendazole. Parasitic worm infestation [1F90] [31]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Trifluoperazine and Safinamide. Parkinsonism [8A00] [55]
Pergolide DM14MAE Moderate Antagonize the effect of Trifluoperazine when combined with Pergolide. Parkinsonism [8A00] [80]
Opicapone DM1BKA6 Moderate Antagonize the effect of Trifluoperazine when combined with Opicapone. Parkinsonism [8A00] [80]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Trifluoperazine and Rasagiline. Parkinsonism [8A00] [55]
Levodopa DMN3E57 Moderate Antagonize the effect of Trifluoperazine when combined with Levodopa. Parkinsonism [8A00] [80]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Pimavanserin. Parkinsonism [8A00] [81]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Trifluoperazine when combined with Bromocriptine. Parkinsonism [8A00] [80]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Orphenadrine. Parkinsonism [8A00] [32]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Methylscopolamine. Peptic ulcer [DA61] [32]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Famotidine. Peptic ulcer [DA61] [40]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [82]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Lefamulin. Pneumonia [CA40] [83]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Degarelix. Prostate cancer [2C82] [34]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Trifluoperazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [84]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Enzalutamide. Prostate cancer [2C82] [34]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Relugolix. Prostate cancer [2C82] [34]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Bicalutamide. Prostate cancer [2C82] [34]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Trifluoperazine and Terazosin. Prostate hyperplasia [GA90] [41]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Trifluoperazine and Silodosin. Prostate hyperplasia [GA90] [41]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Levomepromazine. Psychotic disorder [6A20-6A25] [32]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [85]
Neupro DMHEAB1 Moderate Antagonize the effect of Trifluoperazine when combined with Neupro. Restless legs syndrome [7A80] [80]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Vardenafil. Sexual dysfunction [HA00-HA01] [31]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Trifluoperazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [31]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [31]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [31]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Pitolisant. Somnolence [MG42] [31]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [31]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Trifluoperazine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [86]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Lenvatinib. Thyroid cancer [2D10] [31]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Trifluoperazine and Papaverine. Tonus and reflex abnormality [MB47] [41]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Tacrolimus. Transplant rejection [NE84] [31]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [32]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [38]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [32]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Trifluoperazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [32]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Procainamide. Ventricular tachyarrhythmia [BC71] [31]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Propafenone. Ventricular tachyarrhythmia [BC71] [31]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Trifluoperazine and Flecainide. Ventricular tachyarrhythmia [BC71] [31]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Trifluoperazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [31]
⏷ Show the Full List of 204 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Trifluoperazine 5 mg tablet 5 mg Oral Tablet Oral
Trifluoperazine 10 mg tablet 10 mg Oral Tablet Oral
Trifluoperazine 1 mg tablet 1 mg Oral Tablet Oral
Trifluoperazine 2 mg tablet 2 mg Oral Tablet Oral
Trifluoperazine Hydrochloride 10mg tablet 10mg Tablet Oral
Trifluoperazine Hydrochloride 1mg tablet 1mg Tablet Oral
Trifluoperazine Hydrochloride 2mg tablet 2mg Tablet Oral
Trifluoperazine Hydrochloride 5mg tablet 5mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
6 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
7 Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles
8 Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
9 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
10 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
11 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
12 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
13 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
14 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
17 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
18 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
19 Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
20 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
21 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
22 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
27 Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
28 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
29 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
30 Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
31 Canadian Pharmacists Association.
32 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
33 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
36 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
37 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
38 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
39 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
40 Cerner Multum, Inc. "Australian Product Information.".
41 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
42 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
43 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
44 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
45 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
46 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
47 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
48 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
49 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
50 Multum Information Services, Inc. Expert Review Panel.
51 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
52 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
53 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
54 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
55 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
56 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
57 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
58 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
59 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
60 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
61 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
62 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
63 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
66 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
67 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
68 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
69 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
70 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
71 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
72 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
73 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
74 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
75 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
76 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
77 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
78 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
79 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
80 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
81 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
82 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
83 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
84 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
85 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
86 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".